This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a radiation-responsive nanoparticle drug delivery platform called SCIDD (scintillating nanoparticle drug depot). The goal is to expand the therapeutic window of chemoradiation therapy by using nanoparticles to convert X-ray energy into light that can then trigger the localized release of cytotoxic drugs within irradiated tumor tissue. The $644,034 award will fund research to optimize the SCIDD platform, study its impact on the tumor microenvironment, and assess its ability to safely control disease progression while mitigating systemic toxicity. This work will be conducted by the Research Management division of The General Hospital Corporation, doing business as Massachusetts General Hospital, a major academic medical center and research institution.
Generated 3/25/25, 5:55 AM